All Oncology News

As the dissemination of information in oncology is spread using social media platforms, the potential for misinformation remains a key hurdle.

Krishnansu S. Tewari, MD, details the current and possible future applications of AI in cancer care as well as the limitations of the technology.

Jean-Marc Classe, MD, PhD, discusses omitting lymphadenectomy in patients with advanced epithelial ovarian cancer.

Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.

Saranya Chumsri, MD, and Adam M. Brufsky, MD, PhD, discuss the evaluation of Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer

AHN Cancer Institute’s Centers of Excellence unite teams of experts to provide patients with high-quality, collaborative care in a supportive environment.

The European Commission has approved crovalimab for adult and pediatric patients with paroxysmal nocturnal hemoglobinuria.

Amivantamab plus chemotherapy has received European approval for EGFR-mutant non–small cell lung cancer that progressed on an EGFR TKI.

The FDA has granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions.

OMX-0407 was safe and displayed activity in advanced solid tumors; dose-expansion cohorts will evaluate the agent in RCC and angiosarcoma.

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

Bhavana Pothuri, MD, discusses real-world testing patterns for MMR/MSI status in patients with advanced endometrial cancer.

Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.

Lucia Borriello, PhD, an Assistant Professor at the Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center, has received a $150,000 grant to explore chemotherapy’s role in cancer relapse.

BGB-16673 has received FDA fast track designation for relapsed or refractory CLL or SLL following 2 or more prior lines of therapy.

The European Commission approved odronextamab for patients with relapsed/refractory FL or DLBCL who have received at least 2 prior lines of therapy.

Jason A. Mouabbi, MD, discusses shifting standards for HER2 testing for T-DXd administration and areas of ongoing ADC development within breast cancer.

Shipra Gandhi, MD, discusses the evolution of CDK4/6 inhibitors and ADCs across breast cancer subtypes.

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Bruce G. Haffty, MD, MS, discusses radiation therapy in node-positive breast cancer that becomes node negative after neoadjuvant chemotherapy.

Suzanne Trudel, MSc, MD, discusses updated data from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin–based regimens in R/R multiple myeloma.

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

Krishnansu S. Tewari, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

The FDA has awarded rare pediatric disease designation and orphan drug designation to INV724 for the treatment of neuroblastoma.

A study demonstrates that adding a JAK2 inhibitor to standard immunosuppressive drugs does not improve prevention of acute graft-versus-host disease.

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

The FDA has granted fast track designation to APG-157 for the neoadjuvant treatment of head and neck cancer.

Data from the INSIGHT 2 study showed that tepotinib plus osimertinib elicited responses in patients with EGFR-mutated non–small cell lung cancer.

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.